Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
+$0.27 today
- Market cap
- $695.33M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
Volume 1.13M
Average 1.39M
SLDB Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Solid Biosciences Inc.NASDAQ: SLDB
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $46.14M rose 49.3% year over year, ahead of the +43.4% change in trailing-twelve-month research & development. Sequentially, it rose 21.0% from the prior quarter. Over 3 fiscal years it compounded at +21.4% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +49.3% holds above the trailing-twelve-month pace of +43.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 140.33M USD
- Year-over-year change
- +45.5%
- 4-year CAGR
- +24.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 140.33M | +45.5% |
| FY2024 | 2024-12-31 | 96.43M | +25.9% |
| FY2023 | 2023-12-31 | 76.56M | -2.4% |
| FY2022 | 2022-12-31 | 78.42M | +33.5% |
| FY2021 | 2021-12-31 | 58.74M | — |
Research & Development vs competitors
How SLDB compares with its peers on the latest reported figures
- SLDB's LTM Mar 2026 research & development of $155.55M is the 6th highest of the 10 companies compared; the peer median is $165.37M.
- Its year-over-year change of +43.4% is the 2nd highest of 10, against a peer median of +14.7%.
- Over three fiscal years its annual growth of +21.4% compares with a peer median of +20.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $902.58M | -34.5% | +20.2% | 41.3% | |
| LTM Jun 2026 | $445.71M | +17.2% | +40.8% | — | |
| LTM Jun 2026 | $433.31M | -14.7% | -11.3% | 43.0% | |
| LTM Mar 2026 | $219.98M | +42.7% | +34.6% | 249.3% | |
| LTM Sep 2026 | $165.37M | +14.7% | +41.0% | — | |
| LTM Mar 2026 | $155.55M | +43.4% | +21.4% | — | |
| LTM Mar 2026 | $128.82M | +9.2% | +14.8% | 161.5% | |
| LTM Mar 2026 | $92.92M | +60.8% | +57.0% | — | |
| LTM Mar 2026 | $82.4M | +26.5% | +16.4% | — | |
| LTM Mar 2026 | $58.35M | -32.7% | +9.5% | — | |
| Peer median (excluding SLDB) | $165.37M | +14.7% | +20.2% | 102.2% | |
Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.62M | 8.09M | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 2.58M | 2.46M | 1.64M |
| Gross Profit | 13.62M | 8.09M | (2.58M) | (2.46M) | (1.64M) |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 58.74M | 78.42M | 76.56M | 96.43M | 140.33M |
| Selling, General & Admin | 27.14M | 28.95M | 27.75M | 33.3M | 38.88M |
| Operating Expenses | 85.87M | 114.55M | 101.73M | 127.27M | 177.57M |
| Depreciation & Amortization | 2.96M | 2.41M | 2.58M | 2.46M | 1.64M |
| EBITDA | (69.22M) | (96.87M) | (93.43M) | (121.9M) | (172.69M) |
| EBITDA Margin | -508.3% | -1196.8% | — | — | — |
| Operating Income | (72.25M) | (106.45M) | (104.32M) | (129.73M) | (179.21M) |
| Operating Margin | -530.5% | -1315.2% | — | — | — |
| Interest Income | 64K | 2.62M | 7.14M | 9.47M | 9.9M |
| Interest Expense | 0 | 0 | 0 | 340K | 0 |
| Other Income / Expenses | 66K | 20.47M | 8.3M | 5.03M | 4.88M |
| Income Before Tax | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Pre-Tax Margin | -530.0% | -1062.3% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Net Margin | -530.0% | -1062.3% | — | — | — |
| EPS (Basic) | (10.14) | (10.10) | (4.83) | (3.06) | (1.99) |
| EPS (Diluted) | (10.14) | (10.10) | (4.83) | (3.06) | (1.99) |
| Weighted Avg Shares | 7.12M | 8.51M | 19.88M | 40.82M | 87.5M |
| Weighted Avg Shares (Diluted) | 7.12M | 8.51M | 19.88M | 40.82M | 87.5M |
Solid Biosciences Inc.
NASDAQ:SLDB
Intrinsic Alpha fair value
Locked
Current Price
$6.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.